Increased awareness and knowledge of prostate cancer among the public so more people understand the key facts about prostate cancer and will act on that knowledge.
To provide free, comprehensive one-on-one support to men affected by testicular or prostate cancer.
New Access seeks to develop and trial a new service model to improve access to Low Intensity (Cognitive Behavioural Therapy) treatment for people with mild to moderate depression and anxiety. The program will enable people to access trained coaches for individual-based therapy without having to see a GP first.
A robust, population-wide insight to what matters to patients receiving care and treatment for prostate cancer.
To ensure that those affected by prostate cancer in Hong Kong are assisted to go through the cultural, physical and psychosocial obstacles associated with prostate cancer treatment and reach holistic wellbeing.
To bring experts from across the UK together to improve the treatment and care of men with prostate cancer.
The grant will support high quality, collaborative research that aims to improve diagnosis and treatment for men with prostate cancer.
Night nursing staff will help families to continue to care for men with prostate cancer in a place of their choosing in the last days of their life.
Establish an optimal exercise protocol to maximize quality of life and survival of men with advanced prostate cancer, and unravel the molecular mechanisms underpinning the beneficial effects of exercise in men with advanced disease.
New tests that better predict aggressive prostate cancer from low risk disease so that patient treatment decisions can be optimised at the time of diagnosis.
To improve the implementation of precision medicine through a better understanding of the protein alterations that occur in tumours.
To support innovative prostate cancer research in the field of Immunotherapy. PCF will solicit research proposals that accelerate complete remissions and cures using a “performance enhanced” patient immune system.
The goal of this project is a microscope-to-market development of a medicine that is safe and effective for patients battling metastatic prostate cancer.
Dr. Lang and his team are developing and testing a new blood test that can monitor patient response to treatment, as well as study the emergence of drug resistance